# CHINA BIOTECH SERVICES HOLDINGS LIMITED
# 中國生物科技服務控股有限公司

*(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)*

**(Stock code: 8037)**

## POSITIVE PROFIT ALERT

This announcement is made by China Biotech Services Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 17.10(2)(a) of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the "**GEM Listing Rules**") and the Inside Information Provisions (as defined in the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors (the "**Directors**") of the Company wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that based on information currently available to management of the Company and a preliminary review and assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2026 (the "**Period**"), the Group is expected to record a net profit of not less than HK$15.0 million for the Period, as compared to a net loss of approximately HK$37.0 million for the six months ended 30 June 2025. The expected change from net loss to net profit is mainly attributable to a potential non-cash and unrealised fair value gain on convertible bonds in the range of HK$77.0 million to HK$87.0 million, offset by (i) an increase in finance costs of approximately HK$9.0 million arising from convertible bonds in the principal amount of USD 35 million issued by the Company in February 2026 and (ii) the absence of a non-recurring compensation income of approximately HK$14.0 million arising from an insurance claim which was recognised as other income in the corresponding period in 2025.

As the Company is in the process of preparing the interim results of the Group for the Period, the information above is only based on management's preliminary review and assessment of the unaudited consolidated management accounts of the Group for the Period, which have not been reviewed by the audit committee of the Company and therefore, may be subject to adjustment. The Company expects to announce its unaudited interim results for the Period in late August 2026.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board
**China Biotech Services Holdings Limited**
*Chairman and Executive Director*
**Liu Xiaolin**

Hong Kong, 12 August 2026

*As at the date of this announcement, the Board comprises three executive Directors, namely Mr. Liu Xiaolin (Chairman), Dr. Huang Song and Dr. Yin Ye; and three independent non-executive Directors, namely Mr. Yan Guoxiang, Dr. Guo Yuantao and Dr. Zhang Xiao.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the "Latest Listed Company Information" page of the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.*